The use of gonadotropin-releasing hormone antagonist post-ovulation trigger in ovarian hyperstimulation syndrome.
10.5653/cerm.2017.44.2.57
- Author:
Neil CHAPPELL
1
;
William E GIBBONS
Author Information
1. Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, TX, USA. Neil.Chappell@bcm.edu
- Publication Type:Review
- Keywords:
Antagonist;
Gonadotropin-releasing hormone;
Ovarian hyperstimulation;
Ovarian hyperstimulation syndrome
- MeSH:
Female;
Fertilization in Vitro;
Gonadotropin-Releasing Hormone*;
Humans;
Ovarian Hyperstimulation Syndrome*;
Ovulation;
Population Characteristics
- From:Clinical and Experimental Reproductive Medicine
2017;44(2):57-62
- CountryRepublic of Korea
- Language:English
-
Abstract:
The purpose of this paper is to assimilate all data pertaining to the use of gonadotropin-releasing hormone (GnRH) antagonists in in vitro fertilization cycles after ovulation trigger to reduce the symptoms of ovarian hyperstimulation syndrome (OHSS). A systematic review of the literature was performed to identify all studies performed on the use of a GnRH antagonist in IVF cycle post-ovulation trigger with patients at high risk for OHSS. Ten studies were identified and reviewed. Descriptions of the studies and their individual results are presented in the following manuscript. Due to significant heterogeneity among the studies, it was not possible to perform a group analysis. The use of GnRH antagonists post-ovulation trigger for treatment of OHSS has been considered for almost 20 years, though research into its use is sparse. Definitive conclusions and recommendations cannot be made at this time, though preliminary data from these trials demonstrate the potential for GnRH antagonists to play a role in the treatment of OHSS in certain patient populations.
